MARKET

CTSO

CTSO

Cytosorbents
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.99
-0.25
-3.03%
Opening 14:10 06/16 EDT
OPEN
8.19
PREV CLOSE
8.24
HIGH
8.19
LOW
7.96
VOLUME
85.02K
TURNOVER
--
52 WEEK HIGH
11.74
52 WEEK LOW
7.13
MARKET CAP
346.12M
P/E (TTM)
-37.9032
1D
5D
1M
3M
1Y
5Y
CytoSorbents to Present at the Jefferies Virtual Healthcare Conference
, /PRNewswire/ --  (NASDAQ: CTSO), a critical care leader commercializing its  blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces that the Company will present an overview of...
PR Newswire - PRF · 05/27 11:00
CytoSorbents' CytoSorb blood purification now available in Singapore
CytoSorbents (CTSO) announces that the Singapore Health Sciences Authority ((HSA)) has now approved registration of CytoSorb for all equivalent European Union approved indications, including the reduction of cytokine storm, bilirubin
Seekingalpha · 05/25 11:51
BRIEF-Cytosorb® Registered And Commercially Available In Singapore
reuters.com · 05/25 11:09
CytoSorb® Registered and Commercially Available in Singapore
, /PRNewswire/ --  (NASDAQ: CTSO), a critical care leader commercializing its  blood purification technology to treat deadly conditions in the intensive care unit (ICU) and cardiac surgery, announces that the Singapore Health Sciences Authority (HSA) has ...
PR Newswire - PRF · 05/25 11:08
Market Sentiment Around Loss-Making Cytosorbents Corporation (NASDAQ:CTSO)
We feel now is a pretty good time to analyse Cytosorbents Corporation's ( NASDAQ:CTSO ) business as it appears the...
Simply Wall St. · 05/23 08:11
CytoSorbents to Present at the UBS Global Healthcare Virtual Conference and Oppenheimer MedTech, Tools and Diagnostic Summit
CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces that the Company will present ...
PR Newswire · 05/19 11:00
Avenir Corp Buys Walgreens Boots Alliance Inc, CytoSorbents Corp, Colony Credit Real Estate ...
GuruFocus News · 05/14 21:38
CytoSorbents, Progenity Receive Funding For Product Development
The U.S Army Medical Research and Development Command has awarded CytoSorbents Corporation (NASDAQ: CTSO), a Defense Health Agency (DHA) Sequential Phase II Small Business Innovation Resea
Benzinga · 05/11 19:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CTSO. Analyze the recent business situations of Cytosorbents through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CTSO stock price target is 14.86 with a high estimate of 17.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 143
Institutional Holdings: 18.48M
% Owned: 42.66%
Shares Outstanding: 43.32M
TypeInstitutionsShares
Increased
29
1.03M
New
12
328.02K
Decreased
28
1.45M
Sold Out
14
151.00K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.58%
Healthcare Equipment & Supplies
-0.38%
Key Executives
Non-Executive Chairman/Independent Director
Al Kraus
President/Chief Operating Officer
Vincent Capponi
Chief Executive Officer/Director
Phillip Chan
Chief Financial Officer
Kathleen Bloch
Chief Scientific Officer
Efthymios Deliargyris
Independent Director
Michael Bator
Independent Director
Edward Jones
Independent Director
Alan Sobel
No Data
  • All
  • Financials
  • Insiders
More
About CTSO
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery, autoimmune disease flares, cancer, cytokine release syndrome in cancer immunotherapy and cancer cachexia.

Webull offers kinds of Cytosorbents Corp stock information, including NASDAQ:CTSO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTSO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTSO stock methods without spending real money on the virtual paper trading platform.